235 related articles for article (PubMed ID: 28432778)
1. Cross-species studies of cognition relevant to drug discovery: a translational approach.
Robbins TW
Br J Pharmacol; 2017 Oct; 174(19):3191-3199. PubMed ID: 28432778
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.
Chamberlain SR; Del Campo N; Dowson J; Müller U; Clark L; Robbins TW; Sahakian BJ
Biol Psychiatry; 2007 Nov; 62(9):977-84. PubMed ID: 17644072
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine restores the response inhibition network in Parkinson's disease.
Rae CL; Nombela C; Rodríguez PV; Ye Z; Hughes LE; Jones PS; Ham T; Rittman T; Coyle-Gilchrist I; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
Brain; 2016 Aug; 139(Pt 8):2235-48. PubMed ID: 27343257
[TBL] [Abstract][Full Text] [Related]
4. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat.
Robinson ES; Eagle DM; Mar AC; Bari A; Banerjee G; Jiang X; Dalley JW; Robbins TW
Neuropsychopharmacology; 2008 Apr; 33(5):1028-37. PubMed ID: 17637611
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-HT
Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
[TBL] [Abstract][Full Text] [Related]
6. Effects of atomoxetine on attention and impulsivity in the five-choice serial reaction time task in rats with lesions of dorsal noradrenergic ascending bundle.
Liu YP; Huang TS; Tung CS; Lin CC
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():81-90. PubMed ID: 25151304
[TBL] [Abstract][Full Text] [Related]
7. Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats.
Baarendse PJ; Vanderschuren LJ
Psychopharmacology (Berl); 2012 Jan; 219(2):313-26. PubMed ID: 22134476
[TBL] [Abstract][Full Text] [Related]
8. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
Párraga HC; Párraga MI; Harris DK
Int J Psychiatry Med; 2007; 37(4):415-24. PubMed ID: 18441629
[TBL] [Abstract][Full Text] [Related]
9. Improving response inhibition in Parkinson's disease with atomoxetine.
Ye Z; Altena E; Nombela C; Housden CR; Maxwell H; Rittman T; Huddleston C; Rae CL; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
Biol Psychiatry; 2015 Apr; 77(8):740-8. PubMed ID: 24655598
[TBL] [Abstract][Full Text] [Related]
10. Skin Picking Successfully Treated With Atomoxetine in Comorbid Skin Picking and Attention-Deficit/Hyperactivity Disorder: A Case Report.
Yurteri N; Sarıgedik E
Clin Neuropharmacol; 2020; 43(4):114-115. PubMed ID: 32541332
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
12. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials.
Ravishankar V; Chowdappa SV; Benegal V; Muralidharan K
Asian J Psychiatr; 2016 Dec; 24():53-58. PubMed ID: 27931908
[TBL] [Abstract][Full Text] [Related]
14. Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.
Bradshaw SE; Agster KL; Waterhouse BD; McGaughy JA
Brain Res; 2016 Jun; 1641(Pt B):245-57. PubMed ID: 26774596
[TBL] [Abstract][Full Text] [Related]
15. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
[TBL] [Abstract][Full Text] [Related]
16. Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats.
Bari A; Eagle DM; Mar AC; Robinson ES; Robbins TW
Psychopharmacology (Berl); 2009 Aug; 205(2):273-83. PubMed ID: 19404616
[TBL] [Abstract][Full Text] [Related]
17. Effects of nicotine and atomoxetine on brain function during response inhibition.
Kasparbauer AM; Petrovsky N; Schmidt PM; Trautner P; Weber B; Sträter B; Ettinger U
Eur Neuropsychopharmacol; 2019 Dec; 29(2):235-246. PubMed ID: 30552041
[TBL] [Abstract][Full Text] [Related]
18. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
[TBL] [Abstract][Full Text] [Related]
19. Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications.
Park D; Mabunga DFN; Adil KJ; Ryu O; Valencia S; Kim R; Kim HJ; Cheong JH; Kwon KJ; Kim HY; Han SH; Jeon SJ; Shin CY
Neuropharmacology; 2021 Apr; 187():108494. PubMed ID: 33587920
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.
Ludolph AG; Udvardi PT; Schaz U; Henes C; Adolph O; Weigt HU; Fegert JM; Boeckers TM; Föhr KJ
Br J Pharmacol; 2010 May; 160(2):283-91. PubMed ID: 20423340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
